Ticker brief · 2026-08-23
MRNA MODERNA INC
Phase 3 validation collides with valuation and volatility
Consumer, Non-cyclical · Biotechnology
Lean: bullishlast close
$137.99
1 day
-3.3%
14 days
+117.9%
mkt cap
$31.6B
signals 14d
2,011
authors 14d
700
crowd 14d
+0.9σ
The tape remains bullish, with credible clinical and technical voices outweighing bears focused on valuation, incomplete efficacy disclosure and dilution. The late-week shift was a 14%-17% rebound accompanied by calls leading puts by more than $14M and nearly $20M of November $200 calls. Record volume, violent reversals and elevated implied volatility make this a catalyst-driven trading vehicle rather than a clean fundamental entry.
BULL CAMP
Positive Phase 3 melanoma endpoints validate Moderna's personalized mRNA oncology program and materially reduce platform risk. Bulls argue success in additional tumors could create mega-blockbuster economics, while record volume, underownership and renewed call demand can sustain the repricing.
Key voices@adamfeuersteinHIGHA+1.41@TedHZhangHIGHB+0.57@bioinvestor24MEDIUM-HIGHA-0.45@InvestiBrewMEDIUM-HIGHA+4.14@nextbigtradeMEDIUM-HIGHB+1.10
“Success in lung and other cancers could turn the therapy from a melanoma niche into a mega-blockbuster.”— @adamfeuerstein · tweet ↗
BEAR / SKEPTIC
Bears accept the clinical milestone but argue the stock capitalized broad oncology success before efficacy statistics, commercialization, economics and cross-tumor repeatability are established. They also expect overextension, profit-taking and potential dilution to compress the repricing.
Key voices@BlueDuckCapMEDIUM-HIGHA+1.95@LogicalThesisMEDIUM-HIGHA+2.21@nataninvestingMEDIUM-HIGHB-1.17@DeepSailCapitalMEDIUM-HIGHA-0.47
“The market added $44 billion for a potential $800 million revenue stream still 2-3 years away.”— @BlueDuckCap · tweet ↗
Hypotheses13direction · basis · magnitude · supporters — NEW = first seen this week
▲Positive Phase 3 melanoma endpoints establish the first successful late-stage personalized mRNA cancer-vaccine regimen and materially improve Moderna's outlook.
@adamfeuersteinHIGHA+1.412s · insight@schaeffersHIGHC+3.184s@TedHZhangHIGHB+0.571s · insight@LiveSquawkHIGHB1s@Trade_The_NewsHIGHB+0.942s · insight@BiopharmIQMEDIUM-HIGHB1s+4 more
▲Repeat success across lung and other tumors could validate Moderna's platform broadly and create a mega-blockbuster oncology franchise.
@adamfeuersteinHIGHA+1.413s · insight@bioinvestor24MEDIUM-HIGHA-0.456s · insight@InvestiBrewMEDIUM-HIGHA+4.142s · insight@cnfinancewatchMEDIUM-HIGHB-1.921s · insight@Myeongsu_beanMEDIUM-HIGHB+0.522s · insight@tig88411109MEDIUM-HIGHB+1.393s · insight+2 more
▼The rally capitalizes broad oncology approval and adoption before repeatability, commercialization and economics are proven, creating substantial downside.
@BlueDuckCapMEDIUM-HIGHA+1.952s · insight@LogicalThesisMEDIUM-HIGHA+2.212s · insight@nataninvestingMEDIUM-HIGHB-1.171s@InvestiBrewMEDIUM-HIGHA+4.142s · insight@MacroAlphaHQLOW-MEDIUMA-2.411s · insight@TheRayMyersMEDIUM-HIGHB-1.961s · insight+3 more
▼Omission of Phase 3 efficacy statistics and hazard ratios prevents investors from judging whether endpoint success justifies the valuation.
@BlueDuckCapMEDIUM-HIGHA+1.952s · insight@VladBastionMEDIUM-HIGHB-1.801s · insight@FTMEDIUM-HIGHA-2.692s · insight@eToroMEDIUMC1s@brent_e_traderMEDIUM-HIGHC-0.361s@best181pMEDIUMB-2.731s · insight
▲Specialist underownership and concentrated short interest amplified the surprise readout into forced covering that can continue supporting shares.
@adamfeuersteinHIGHA+1.412s · insight@S3PartnersMEDIUM-HIGHA2s · insight@semodoughMEDIUM-HIGHC-3.011s@SixSigmaCapitalMEDIUM-HIGHB-0.401s · insight@BullTheoryioMEDIUM-HIGHC-1.571s@newsinvestingMEDIUM-HIGHC1s+2 more
▲Record upside volume and a Stage 2 episodic-pivot breakout indicate durable institutional repricing rather than a routine news spike.
@nextbigtradeMEDIUM-HIGHB+1.106s · insight@TedHZhangHIGHB+0.573s · insight@cevikfinanceMEDIUM-HIGHC-1.352s@sspencer_smbHIGHA+1.471s · insight@MARU_XMEDIUMC-1.272s@FranVezzMEDIUM-HIGHC-2.121s+1 more
▼Heavy second-day selling, extreme overextension and failed follow-through indicate the initial breakout is vulnerable to a deeper gap retracement.
@nextbigtradeMEDIUM-HIGHB+1.102s · insight@cantonmeowHIGHB-2.352s · insight@Chart_GuyLOW-MEDIUMC-0.632s@MitchMartan98MEDIUMC-0.693s@jd_durkinHIGHC-0.621s@AmeetRaiHIGHC-1.081s+1 more
▲The late-week rebound and reclaim of prior highs support continuation toward $159.47-$170 if those resistance levels convert to support.
@TedHZhangHIGHB+0.572s · insight@Sinus84MEDIUMC+0.091s@joealertzMEDIUM-HIGHC-2.722s@RealHeel80MEDIUMC-1.493s@LaMonicaBuzzHIGHB+0.091s@HyenukChuMEDIUM-HIGHC+0.971s+1 more
▼Moderna may exploit the elevated share price with a large secondary offering, creating near-term dilution and supply pressure.
@BlueDuckCapMEDIUM-HIGHA+1.953s · insight@2000STOCKMASTERLOWC+1.053s@epictrades1MEDIUM-HIGHC+1.451s@DeepSailCapitalMEDIUM-HIGHA-0.471s · insight@stockgutterMEDIUM-HIGHB+0.781s · insight@jbulltard1MEDIUMC+0.261s+2 more
▲Late-week call buying and put selling indicate renewed upside positioning after the selloff, with speculative demand extending toward $200.
@QuantDataMEDIUM-HIGHC2s@StockOptionColeMEDIUMC-3.291s@CheddarFlowMEDIUM-HIGHC1s@johnschartsHIGHC-2.201s@TraderJonesyLOW-MEDIUMC-0.451s@buzztickrLOW-MEDIUMC1s
◆Extreme implied volatility favors hedged premium-selling structures over outright directional exposure while post-catalyst volatility begins reverting.
@Sinus84MEDIUMC+0.094s@RealDayTradingMEDIUM-HIGHB-1.982s · insight
◆The Moderna readout is accelerating capital rotation into biotechnology and healthcare while semiconductors and other prior leaders lose momentum.
@SPYJaredHIGHB+0.071s · insight@NickDrendelMEDIUMC-1.091s@PersimmonTIMEDIUM-HIGHA-0.571s · insight@anandragnMEDIUM-HIGHC-1.171s@gmorton512MEDIUM-HIGHC+0.151s@ValckrieMEDIUM-HIGHC-1.821s+1 more
▲Planned regulatory filings following the Phase 3 stop create the next discrete catalyst, although approval still requires complete data review.
@BiopharmIQMEDIUM-HIGHB1s@BPharmCatalystMEDIUM-HIGHC1s@InvertirDesde0MEDIUMC+0.191s@MacroAlphaHQLOW-MEDIUMA-2.411s · insight@MDividende12LOW-MEDIUMC+1.471s
Direct calls5authors taking explicit directional positions
@tig88411109MEDIUM-HIGHB+1.39
Scale into MRNA in layers across favorable valuation and support zones.
@tradertvshawnMEDIUM-HIGHC-2.42
Long MRNA in size after another move toward $140.
@AdnansArkMEDIUMC-1.01
Added MRNA for a multiweek four-hour swing into next week.
@IPODaveMEDIUM-HIGHB+1.63
MRNA will likely give back gains toward $100 over the coming weeks.
@MarcosMillaYTMEDIUMC+0.81
Expect Moderna to trade below $100 soon.
Sellside activity8
RBC pt_raise PT 130 (from 45)Maintained Sector Perform and said valuation already reflects estimated oncology upside.
BofA upgradeUpgraded Moderna to Neutral after intismeran results materially changed the investment story.
Morgan Stanley pt_raise PT 89 (from 39)Retained Equal Weight after raising its target.
JPMorgan pt_raise PT 77 (from 40)Maintained Underweight despite the target increase.
Citi reiterate PT 60Maintained Neutral while questioning the commercial relevance of the positive trial data.
William Blair upgradeUpgraded MRNA to Outperform following the positive Phase 3 data.
Freedom Capital noteJay Woods called the post-data strength a buy while using the opening gap as the floor.
Mizuho noteCommentary was constructive on Moderna's rally following the new cancer-shot data.
News / data points5discrete events + data quoted by authors
@adamfeuersteinHIGHA+1.41
The Phase 3 trial stopped positively after the combination slowed melanoma recurrence and spread.
@BiopharmIQMEDIUM-HIGHB
Positive Phase 3 melanoma endpoints were followed by plans for regulatory filings.
@nextbigtradeMEDIUM-HIGHB+1.10
MRNA traded at 15 times average daily volume during 2026's largest Stage 2 breakout.
@QuantDataMEDIUM-HIGHC
Late-week bullish positioning had calls leading puts by more than $14M.
@StockOptionColeMEDIUMC-3.29
Nearly $20M of November MRNA $200 calls were purchased.
Position disclosures3skin in the game
@nextbigtradeMEDIUM-HIGHB+1.10
Ended August 19 long MRNA after the record-volume breakout.
@GassionGretaMEDIUMC+0.31
Opened an 11% MRNA position with an 8% chart-based stop, then reported loading up before the rebound.
@commonsenseplayMEDIUMC-0.19
Opened an MRNA short at $152.
Desk readconvergence assessment
There is strong convergence that the Phase 3 result is scientifically meaningful, but little agreement on how much oncology success the stock should capitalize before full data and commercialization. Bulls have broader high-credibility clinical and tape support, while the strongest bears are also credible and focus on missing efficacy statistics, economics and dilution rather than denying the endpoint result. Several active bulls have cold trader scores, including Pharmdca at -2.82 and nextbigtrade at -2.93, so confirmation requires sustained closes above $159.47-$170 and broader-tumor validation; loss of the gap and evidence of an equity raise would favor the bear case.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 71% mid · 39 pctile own 1y | IV/HV 0.35× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | +0.072 92 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +5.02 elevated | 5-session Δ +1.28 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-01-23 (z=2.8) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now +0.16 (−1 bearish … +1 bullish)
Who spoke700
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @joealertz | C | -2.72 | 39 | +0.58 |
| @RapidTrading | C | -0.87 | 32 | +0.51 |
| @nextbigtrade | B | +1.10 | 28 | +0.50 |
| @bioinvestor24 | A | -0.45 | 28 | +0.38 |
| @RealHeel80 | C | -1.49 | 27 | +0.28 |
| @twinsight_x | C | +0.96 | 24 | +0.39 |
| @DekmarTrades | C | -1.24 | 23 | +0.33 |
| @MWM76 | C | -1.00 | 20 | +0.42 |
| @Pharmdca | C | +0.82 | 17 | +0.49 |
| @fundmyfund | B | -1.58 | 17 | +0.25 |
| @adamfeuerstein | A | +1.41 | 15 | +0.30 |
| @TedHZhang | B | +0.57 | 15 | +0.61 |
| @Mr_Derivatives | C | -2.57 | 15 | +0.20 |
| @NirAoo7 | C | -1.18 | 15 | +0.14 |
| @schaeffers | C | +3.18 | 13 | +0.39 |
| @TravisBiziorek | C | -2.39 | 13 | +0.47 |
| @SpartanTrading | C | -1.46 | 13 | +0.58 |
| @robertojirusta | C | -0.22 | 12 | +0.26 |
| @tig88411109 | B | +1.39 | 12 | +0.59 |
| @cfaryanoconnell | C | -1.48 | 12 | +0.31 |
| @theincomewheel | C | -1.37 | 11 | +0.56 |
| @tradertvshawn | C | -2.42 | 11 | +0.37 |
| @MARU_X | C | -1.27 | 11 | +0.40 |
| @Sinus84 | C | +0.09 | 11 | +0.15 |
| @ShardiB2 | C | -0.13 | 10 | +0.57 |
Recent signals30of 2,011 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @IncomeETFDaily | +0.10 | Provides detailed strategy, yield, holdings, assets and 2026 performance statistics for MRNY. | — | tweet ↗ |
| 2026-08-28 | @ScrooogeUncle | +0.35 | Uses an alleged Moderna AI cancer breakthrough to argue strongly for AI's benefits. | — | tweet ↗ |
| 2026-08-28 | @DarvasBoxAI | +0.70 | Discloses an existing MRNA long and expects consolidation before possible upside. | — | tweet ↗ |
| 2026-08-28 | @bioinvestor24 | +0.55 | Discloses no MRNA position but a positive trial view, and states a current HK1952 position viewed as undervalued. | — | tweet ↗ |
| 2026-08-28 | @FINTECHTVglobal | +0.40 | Reports bullish analyst actions for Amazon, Burlington and Moderna. | — | tweet ↗ |
| 2026-08-28 | @bioinvestor24 | +0.65 | Mocks BNTX's colorectal-cancer strategy and favors MRNA's platform and tumor-selection approach. | — | tweet ↗ |
| 2026-08-28 | @bulioscom | +0.55 | Newsletter teaser cites MRNA's 176.97% jump and CVX Venezuela output. | — | tweet ↗ |
| 2026-08-28 | @PrintingTendies | -0.40 | Recaps a 5,820% CRM call gain while mocking losses in four other names | — | tweet ↗ |
| 2026-08-28 | @ElliottForecast | +0.85 | Projects MRNA's confirmed Wave III breakout toward $200-$210, then potentially $250. | — | tweet ↗ |
| 2026-08-28 | @joealertz | +0.45 | Watches $145 calls if Moderna clears $140, but does not state entry intent. | — | tweet ↗ |
| 2026-08-28 | @BiotechCH | +0.70 | The MRNA-MRK cancer-vaccine trial hit recurrence and metastasis-free survival endpoints. | — | tweet ↗ |
| 2026-08-28 | @BiotechCH | +0.20 | Discusses XBI's positive trend and adverse benchmark effects from MRNA's influx. | — | tweet ↗ |
| 2026-08-28 | @ClassicRoy | +0.00 | Lists options with decreasing implied volatility. | — | tweet ↗ |
| 2026-08-28 | @801010athlete | +0.65 | Detailed portfolio update lists current holdings, cash, realized MRNA gains and stopped positions. | — | tweet ↗ |
| 2026-08-28 | @BiotechCH | +0.60 | Biotech show agenda summarizes several material trial, financing and approval events. | — | tweet ↗ |
| 2026-08-28 | @TBU12345678 | +0.35 | Argues AI value must shift from semiconductors toward users, favoring drug discovery and bioprocessing. | — | tweet ↗ |
| 2026-08-28 | @RealtorStarShar | -0.75 | Explicitly urges Moderna shares lower | — | tweet ↗ |
| 2026-08-28 | @BenzingaSpain | -0.25 | Moderna expands convertible debt to fund oncology growth as shares decline | — | tweet ↗ |
| 2026-08-28 | @AmeetRai | -0.30 | Avoids MRNA until extreme volatility and wide ranges tighten. | — | tweet ↗ |
| 2026-08-28 | @twinsight_x | -0.50 | Multi-ticker level sheet gives resistance, support and target levels without explicit entries. | — | tweet ↗ |
| 2026-08-28 | @RealHeel80 | +0.35 | Will keep taking entries near the pivot despite possible chop. — Describes a second entry near 120 and intent to keep taking shots. | — | tweet ↗ |
| 2026-08-28 | @NirAoo7 | -0.60 | Trying a new APPS long after stopping out of MRNA. — Reports completed MRNA stop-out and a new APPS attempt; the forward APPS entry is primary. | — | tweet ↗ |
| 2026-08-28 | @RealHeel80 | +0.05 | Watchlist note cites the 10-day EMA and August 20 low. | — | tweet ↗ |
| 2026-08-28 | @Ollie_AllCaps | +0.10 | Identifies 132.4 as an MRNA area of interest without entry intent. | — | tweet ↗ |
| 2026-08-28 | @joealertz | +0.40 | Watches for Moderna to break $140 and turn positive on the day. | — | tweet ↗ |
| 2026-08-28 | @Gubloinvestor | -0.75 | Highlights Moderna's fall from $176 to $136 and calls holders trapped. | — | tweet ↗ |
| 2026-08-28 | @fundmyfund | -0.60 | Reports MRNA breaking below the prior day's lows. | — | tweet ↗ |
| 2026-08-28 | @ttvresearch | -0.30 | BioNTech ended a Phase 2 colorectal-cancer trial, prompting sharp declines in related biotech shares. | — | tweet ↗ |
| 2026-08-28 | @StonkValue | +0.10 | Reports modest Q2 revenue growth with a mixed revenue composition. | — | tweet ↗ |
| 2026-08-28 | @PolymarketMoney | -0.45 | Moderna and Merck fall after BioNTech halted a Phase 2 colorectal-cancer vaccine trial. | — | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.